Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung

In brief

The purpose of this study is to learn whether it is better to receive the drug Metformin with standard of care for lung cancer or just standard of care.

Key facts

Study ID

NCT01717482

Run by

Mayo Clinic

People needed

6

Starts

2012-10-01

Expected to finish

2019-05-22

Last updated by the study team

2020-03-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Suspected or biopsy proven Stage IA-IIIA lung squamous cell carcinoma (SCC) (must be proven SCC at the time of surgery)
• Medically fit for surgical resection (based on surgeon assessment)
• Current or prior smoker
• Age > 18 years old
• Both Male and Female
• Willing and able to consent to study, undergo study interventions, and take study drug
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2
• Subject must start Metformin within 90 days of surgery.

You may not qualify if…

• Currently taking metformin or other diabetic drugs
• Current or previous congestive heart failure, renal failure or liver failure
• Creatinine in Women of 1.4 or greater and Creatinine in Men of 1.5 or greater
• Existing untreated or prior cancer <5 years from diagnosis
• Received neo-adjuvant platinum-based chemotherapy or targeted therapy
• Receiving adjuvant platinum-based chemotherapy or targeted therapy after surgical resection

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.